We are excited to be hosting Tribe Public's Next Webinar Presentation and Q&A Event which will be held Tuesday, February 2 (8 am PT/ 11 am ET). Our FREE webinar events are approximately 30 minutes in duration.
Steven Quay, MD, PhD, CEO & Founder & Kyle Guse CFO of Atossa Therapeutics (NASDAQ: ATOS) will deliver a presentation titled "The Important Role of COVID-19 Therapeutics In A Post-Vaccine World." They will be also be available for a 5-10 minute Q&A session at the end of the presentation. Send Questions to email: research@tribepublic.com.
Dr. Quay is an author, entrepreneur, and accomplished physician-scientist that has founded six startups invented seven FDA-approved pharmaceuticals and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. He received his M.D., M.A., and Ph.D. from The University of Michigan. He was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana and a resident at the Harvard-Massachusetts General Hospital. He was on the faculty of Stanford University School of Medicine for almost a decade. His current passions are big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancers in the world each year. His website is www.drquay.com.
He also recently published the following book “Your COVID-19 Survival Manual: A Physician’s Guide to Keep You and Your Family Healthy During the Pandemic and Beyond,” and will be offering a significant discount code to all that will be attending his Tribe Zoom Webinar meeting on July 30th. Proceeds from the book will go to military veterans performing COVID-19 relief work in their communities. Please send us an email at research@tribelublic.com to request that we send you a FREE electronic copy via Amazon.
Atossa Therapeutics (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19. Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.
We will be limited to 100 seats for this event and have a nice group confirmed already, so please reply quickly.